According to reports in the New York Times and on FiercePharma, the FDA and the generic pharmaceutical industry has reach agreement on annual user fees of just under $300 million to cover inspections of foreign manufacturing plants every 2 years. It is being predicted that Congress will give its approval to this agreement.For more details see
- "Government, generic industry reach agreement on fees" by Liz Jones Hollis, published today on the FiercePharma web site.
- "Inspection deal aims to improve generic drugs" by Gardiner Harris in the New York Times from Saturday, August 13.